TriangleHEALTH PROFESSIONAL · SOURCE READING
Clinical trials
Source: Endometrial Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
All patients with advanced disease should consider clinical trials that evaluate single-agent or combination therapy for this disease.
Studies of treatment failure patterns have found a high rate of distant metastases in the upper abdomen and in extra-abdominal sites.[35] For this reason, patients with stage III disease may be candidates for innovative clinical trials.
Source links and citations
Treatment options under clinical evaluation for stage IV endometrial cancer include the following agents:
Paclitaxel and carboplatin with or without metformin in stages III, IV, and recurrent endometrial cancer (GOG-0286B [NCT02065687]).
Source links and citations
PI3K/mTOR inhibitor in recurrent or persistent endometrial cancer (15-079 [NCT02549989]).
Source links and citations
Everolimus and letrozole or hormonal therapy in recurrent or persistent endometrial cancer (GOG-3007 [NCT02228681]).
Source links and citations
Everolimus, letrozole, and metformin in advanced or recurrent endometrial cancer (2012-0543 [NCT01797523]).
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice